SINGAPORE'S Novena Global Healthcare has bagged US$20 million in investment from Sinopharm Capital and Cedarlake Capital Group.
The US$20 million investment will be used to grow the Singapore aesthetic healthcare firm's existing business in China and South-east Asia. This is while leveraging on Sinopharm Capital’s network and resources for its China expansion. Nelson Loh, executive chairman and co-founder of DORR Group and Novena Global Lifecare, said the company will continue to innovate and disrupt the lifecare industry around the region.
Wir haben diese Nachrichten zusammengefasst, damit Sie sie schnell lesen können. Wenn Sie sich für die Nachrichten interessieren, können Sie den vollständigen Text hier lesen. Weiterlesen: